Arcus Biosciences
RCUS · Nasdaq · United States
Share price · RCUS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when RCUS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 21 Oct 2026-19.6%
- 24 Sep 2026-5.0%
Nothing announced by RCUS that day or the session before.
- 11 Sep 2026-6.0%
Nothing announced by RCUS that day or the session before.
- 10 Sep 2026-8.2%
Nothing announced by RCUS that day or the session before.
- 22 Jun 2026+12.0%
Nothing announced by RCUS that day or the session before.
- 22 Apr 2026+8.6%
Nothing announced by RCUS that day or the session before.
- 21 Apr 2026+7.8%
- Day beforeArcus Biosciences: Other material event
- 2 Mar 2026+17.5%
Nothing announced by RCUS that day or the session before.
- 15 Jan 2026-11.3%
Nothing announced by RCUS that day or the session before.
- 13 Jan 2026+6.8%
Nothing announced by RCUS that day or the session before.
Share of unusual movement by asset
For each asset, the share of RCUS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | HIF-2alphaSmall molecule | Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma | |
| Phase 3 | CD73 (NT5E)Small molecule | Pancreatic Ductal Adenocarcinoma | |
| Phase 1 | CD39 (ENTPD1)Monoclonal antibody | Non-Small Cell Lung CancerGastric Cancer | |
| Phase 1 | AXLSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
What to watch
2028 (1)
April 2028 (1)
What to watch
2030 (1)
November 2030 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $3.0M | $117M | $151M+ $479M short-term inv. | $128M-$88M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $33M | $113M | $150M+ $552M short-term inv. | $91M-$119M operating cash flow | report ↗ |
| 2026-Q1 | $7.0M | $122M | $201M+ $621M short-term inv. | $128M-$138M operating cash flow | report ↗ |
| 2025-Q3 | $6.0M | $141M | $238M+ $593M short-term inv. | $135M-$97M operating cash flow | report ↗ |
| 2025-Q2 | $8.0M | $139M | $248M+ $663M short-term inv. | —-$133M operating cash flow | report ↗ |
| 2025-Q1 | $8.0M | $122M | $192M+ $805M short-term inv. | $112M-$132M operating cash flow | report ↗ |
| 2024-Q3 | $48M | $123M | $201M+ $888M short-term inv. | $92M$26M operating cash flow | report ↗ |
| 2024-Q2 | $39M | $115M | $156M+ $813M short-term inv. | $93M-$94M operating cash flow | report ↗ |
| 2024-Q1 | $145M | $109M | $185M+ $810M short-term inv. | $4.0M-$2.0M operating cash flow | report ↗ |
| 2023-Q3 | $32M | $82M | $184M+ $615M short-term inv. | $71M-$63M operating cash flow | report ↗ |
| 2023-Q2 | $29M | $84M | $230M+ $700M short-term inv. | $75M-$57M operating cash flow | report ↗ |
| 2023-Q1 | $25M | $81M | $238M+ $716M short-term inv. | $80M-$98M operating cash flow | report ↗ |
| 2022-Q3 | $34M | $77M | $218M+ $831M short-term inv. | $65M-$81M operating cash flow | report ↗ |
| 2022-Q2 | $27M | $70M | $273M+ $900M short-term inv. | $67M-$65M operating cash flow | report ↗ |
| 2022-Q1 | $18M | $61M | $549M+ $665M short-term inv. | $68M$654M operating cash flow | report ↗ |
| 2021-Q3 | $9.5M | $71M | $179M | $78M-$54M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $247M | $523M | $1.0B | $353M | report ↗ |
For fiscal year 2025, Arcus Biosciences reported revenue of $247M, down 4.3% YoY, with R&D spend of $523M, up 16.7% YoY. Cash and equivalents stood at $1,000M. Net income or loss was not disclosed, and quarterly net burn was $353M.
No formal financial guidance was provided, but the company highlighted clinical progress: the Phase 3 PEAK-1 trial of casdatifan with cabozantinib is enrolling, a second Phase 3 casdatifan study in a TKI-free first-line regimen is targeted to begin by the end of 2026, and the Phase 3 PRISM-1 study completed enrollment in September 2025 with results expected in the first half of 2027. Arcus also disclosed a December 2025 announcement regarding its Phase 3 STAR-221 trial of domvanalimab, and a temporary pause in recruitment for the eVOLVE-RCC02 study after immune-mediated adverse events were observed.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $258M | $448M | $992M | $282M | report ↗ |
| 2023-FY | $117M | $340M | $127M+ $632M short-term inv. | $77M-$306M operating cash flow | report ↗ |
| 2022-FY | $112M | $288M | $206M+ $803M short-term inv. | $67M$438M operating cash flow | report ↗ |
| 2021-FY | $383M | $256M | $148M+ $351M short-term inv. | —-$256M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 32 sales ($9.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-21 | Azoy Alexander · Chief Accounting Officer | Option exercise | 2,827 | $15.44 | $44K | Form 4 |
| 2026-08-21 | Azoy Alexander · Chief Accounting Officer | Open-market sale | 2,827 | $30.00 | $85K | Form 4 |
| 2026-08-21 | Azoy Alexander · Chief Accounting Officer | Option exercise (derivative) | 2,827 | — | — | Form 4 |
| 2026-07-10 | Jaen Juan C. · President | Open-market sale | 19,799 | $28.61 | $566K | Form 4 |
| 2026-07-10 | Jaen Juan C. · President | Open-market sale | 268 | $29.40 | $8K | Form 4 |
| 2026-07-09 | Jaen Juan C. · President | Open-market sale | 48,502 | $30.05 | $1.5M | Form 4 |
| 2026-06-24 | Jaen Juan C. · President | Open-market sale | 6,431 | $29.66 | $191K | Form 4 |
| 2026-06-23 | Jaen Juan C. · President | Open-market sale | 14,067 | $27.69 | $389K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 210 reporting institutions held 119.1M shares ($2.6B, 82.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | GILEAD SCIENCES, INC. | 31,424,760 | $678.8M |
| 2 | BlackRock, Inc. | 15,226,475 | $328.9M |
| 3 | WELLINGTON MANAGEMENT GROUP LLP | 6,089,516 | $131.5M |
| 4 | STATE STREET CORP | 5,412,901 | $116.9M |
| 5 | SUVRETTA CAPITAL MANAGEMENT, LLC | 5,030,993 | $108.7M |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4,272,056 | $92.3M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 3,856,725 | $83.3M |
| 8 | Woodline Partners LP | 3,777,798 | $81.6M |
| 9 | MARSHALL WACE, LLP | 3,761,437 | $81.2M |
| 10 | Siren, L.L.C. | 3,007,077 | $65.0M |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 2,252,367 | $48.7M |
| 12 | Fisher Asset Management, LLC | 2,190,404 | $47.3M |
| 13 | SAMLYN CAPITAL, LLC | 1,908,412 | $41.2M |
| 14 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,654,754 | $35.7M |
| 15 | DIMENSIONAL FUND ADVISORS LP | 1,426,223 | $30.8M |